We participate in European research in our own right and through our membership of the Stroke Alliance for Europe (SAFE), a not-for-profit organisation that represents stroke survivor groups across the continent.
We have experience of several European stroke research projects and new proposals are always in development. Our major strength is dissemination and our involvement in clinical trials helps patient organisations stay up-to-date with the latest research developments, and also ensures that this potential live-saving knowledge reaches patients and healthcare professionals all across Europe.
There remain significant challenges to delivering the consistent, high standard of rehabilitative therapy that stroke survivors need to achieve their best possible long-term outcomes.
The Mobile Assistance for Groups and Individuals in the Community (MAGIC) project is funded by a €3.6m (£2.7m) award from the EU’s Horizon 2020 programme. It is managed by a Northern Ireland led international consortium of research, governmental and independent organisations.
MAGIC aims to discover innovative approaches to post-stroke care based on Information Communications Technology (ICT) solutions. These include virtual reality, wearable sensor technology, and telemedicine approaches. All aim to enable stroke survivors to have a higher quality of life and reduced need for long-term care.
To help achieve its goal, MAGIC involves a number of industry suppliers competing through several phases of solution development and testing. In November 2017, MAGIC entered its second phase of testing with four industry suppliers. Results from the project are expected in September 2019.
Find out more about the MAGIC project.
The Stroke Association is part of the Expert Advisory Panel of the MAGIC Project.
Contact our Director of Northern Ireland firstname.lastname@example.org for more information.
An ischaemic stroke is the most common type of stroke. The arteries that supply the brain with blood become clogged by clots. This kills the brain cells at the centre of the stroke and puts those brain cells nearby at great risk of damage.
High-dose oxygen therapy is very simple and low-cost. After having been diagnosed with an ischaemic stroke, the patient wears a mask through which they inhale almost pure oxygen. This keeps the oxygen content in the blood as high as it can be.
The aim of the PROOF trial is to ensure that the surrounding brain tissue at risk, which will have less oxygen but is not yet dead, is stabilised by high oxygen content coming in. This continues until the clot is removed by emergency treatment and the blood circulation is improved again.
The Stroke Association is a member of the Stroke Alliance For Europe (SAFE), which will work on communication of information about the PROOF trial to non-clinical audiences.
To find out more about the PROOF trial, visit the SAFE website.
A key cause of both stroke and dementia is known as ‘small vessel disease’ or ‘SVD’ for short.
There are many types of SVD which can damage the small blood vessels in the brain, gradually starving it of the oxygen and food it needs. This leads to harmful changes in the brain’s structure. These changes cause about a third of all strokes, and at least two out every five cases of dementia. However, despite this huge impact, there are still no treatments that are proven to help.
The SVDs @target programme aims to learn more about the biological mechanisms behind SVD, so that one day we may stop SVDs from ever developing.
About 20% of strokes occur during sleep and the exact time the stroke started will not be known.
But, the best treatment available has to be given within 4.5 hours of the stroke onset.
The WAKE-UP trial uses advance brain imaging to decide if the stroke started within the 4.5 hour window.
For the latest trial updates, visit the WAKE-UP website.
The EuroHYP-1 trial is a large, international clinical trial that will test whether a promising new intervention called ‘therapeutic hypothermia’ can improve the outcome for patients with ischemic stroke (a stroke caused by a blood clot).
Therapeutic hypothermia means lowering the body by a few degrees and it is used to protect the body tissues from damage when they are not receiving enough oxygen.
Within six hours of symptom onset, patients enrolled in the trial will have their core body temperature reduced to 34-35°C for 24 hours.
For the latest information about the trial, please visit the EuroHYP-1 website.
Many stroke survivors are unable to perform ordered sequences of movements that are necessary to complete everyday tasks such as making a cup of tea or brushing their teeth. The difficulty isn't with physically making the movements, but damage to the brain can cause cognitive impairment which means that knowledge of the actions and objects used in the task is lost.
CogWatch developed intelligent everyday objects such as those used in tea-making and toothbrushing. The objects 'know' how they are being used and they 'talk' to a tablet screen to give prompts to the user if they make errors.
A major collaborative research program has now launched to develop new ways to support self-management by stroke survivors in their homes.
Called STARR, (decision support and self-management system for stroke survivors) the new program will target the known risk factors for recurrent stroke, as it is estimated that 90% of recurrent strokes are preventable if the risk factors are managed appropriately.
STARR will develop a modular, affordable, and easy-to-use system, which will inform stroke survivors of the relationship between their daily activities (for example, their medication intake, physical and cognitive exercises, diet, and social contacts) and their risk of having a further stroke.
STARR is run in partnership by a European consortium of researchers and will receive 4.5 million euros from the EU Horizon 2020 research program. The consortium includes stroke survivors and their representatives, commercial healthcare companies, hospitals, as well as sensing technology, privacy and human-machine interaction research groups from seven countries.
Contact email@example.com for further information
The PRECIOUS trial is a Horizon 2020 funded research project that started in June 2015.
In the first few days after stroke, about half of the patients have complications, including:
- swallowing problems.
These complications are strongly associated with a higher risk of death or future disability.
PRECIOUS is a large clinical trial, with 3,800 patients aged 66 years or older with acute stroke, that assesses the impact of pharmacological prevention of these frequent complications.
PRECIOUS uses cheap, off-the-shelf medications that are simple, safe and readily available.
It has the potential to lead to an annual reduction of over 25,000 elderly Europeans prematurely dying or being left dependent as a result of stroke.
Contact our European Research Manager via firstname.lastname@example.org for more information.
The European Union will fund stroke under it's Horizon 2020 research programme. We seek partnerships in EU proposals on any topic on the stroke pathway.
- Authentic patient voice, this is vital for proposal success
- First class multi-channel dissemination around project plans, visibility and results
- Requirements gathering and evaluation work
- Guidance on consortium building and proposal writing.
Please contact Dr. Gary Randall for further information and collaboration details.